Get the Stockscreener App
3.31
3.76%
0.12
After Hours:
3.33
0.02
+0.60%
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio (NASDAQ:IBRX) Shares Up 17.2%Time to Buy? - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Down 6.8%Here's What Happened - MarketBeat
ImmunityBio and BeiGene ink research collaboration - The Pharma Letter
D. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio Continues Trimming Workforce While Working to Advance Anktiva - BioSpace
Why Immunitybio Inc. (IBRX) Soared on Thursday - Insider Monkey
Here’s Why ImmunityBio, Inc. (IBRX) Will Double in 2025 - Insider Monkey
ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo - Yahoo Finance
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism - MSN
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene - MarketWatch
Why ImmunityBio Stock is Gaining Momentum - TipRanks
ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy - Marketscreener.com
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire
Game-Changing Cancer Trial: How This Biotech Partnership Could Transform Lung Cancer Treatment - StockTitan
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital - MarketBeat
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - BioSpace
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA - Business Wire
ImmunityBio (NASDAQ:IBRX) Trading Down 4.2%What's Next? - MarketBeat
ImmunityBio: Despite Anktiva's Clinical Promise, Remains A Difficult Investment (IBRX) - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Stock Quotes, Forecast and News Summary - Benzinga
ImmunityBio, Inc. (IBRX) Stock: An Under $5 Gem with Biggest Upside Potential - Insider Monkey
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK - MSN
Why Did Immunitybio (IBRX) Go Down on Friday? - MSN
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally - Insider Monkey
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Update - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpTime to Buy? - MarketBeat
JPMorgan Chase & Co. Has $4.24 Million Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
D. Boral Capital Reaffirms “Buy” Rating for ImmunityBio (NASDAQ:IBRX) - Defense World
ImmunityBio stock gains 15% amid regulatory updates - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.2%What's Next? - MarketBeat
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval (Upgrade) (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Target of Unusually Large Options Trading (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Up 6.3%Here's Why - MarketBeat
ImmunityBio (NASDAQ:IBRX) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Investors Purchase Large Volume of Call Options on ImmunityBio (NASDAQ:IBRX) - Defense World
Why ImmunityBio, Inc. (IBRX) Is Skyrocketing - MSN
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details - Benzinga
ImmunityBio stock gains 15% amid regulatory updates (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances - MarketWatch
ImmunityBio shares surge following progress in FDA discussions By Investing.com - Investing.com Canada
ImmunityBio shares surge following progress in FDA discussions - Investing.com
Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday - Benzinga
Anktiva targets expanded indication in US and global approvals in EU and UK - Urology Times
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):